A novel ERK-pathway inhibitor (PD098059) arrests invasion and growth of HNSCC in a murine model
Détails
ID Serval
serval:BIB_96DEE4873D0D
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Institution
Titre
A novel ERK-pathway inhibitor (PD098059) arrests invasion and growth of HNSCC in a murine model
Titre de la conférence
International Symposium on Metastases in Head and Neck Cancer
Adresse
Kiel, Germany, January 15-18, 1998
ISBN
1532-1827
ISSN-L
0007-0920
Statut éditorial
Publié
Date de publication
1998
Volume
77
Série
British Journal of Cancer
Pages
47
Langue
anglais
Notes
Meeting Abstract
Résumé
The prognosis for patients with HNSCC is intimately linked to
invasion of adjacent tissues. Thus, inhibition of protease expression
in HNSCC via interference with signal transduction pathways may
reduce invasive properties and improve survival. Recently, we have
shown that a specific ERK-pathway inhibitor ( PD 098059 ) arrests
invasion of UM-SCC1 cells in-vitro. We therefore investigated the
effect of PD 098059 on this cell line in-vivo. Using a quantitative
orthotopic murine model, stepwise invasion of the floor-of-mouth
and tongue were evaluated after subcutaneous tumour cell
injection. Intralesional administration of PD 098059 using
liposomes as a carrier was performed over a 25 day period (every
5 days with 15mM final concentration). Tumor growth arrest and
attenuation of tumor invasion occurred in 3 of 4 treated mice;
while tumor advanced into the genioglossus muscle in 4 of 5
control mice.
Therefore the inhibition of the ERK-signal transduction pathway
may become a powerful therapeutic adjuvant in combating invasion
ofHNSCC.
invasion of adjacent tissues. Thus, inhibition of protease expression
in HNSCC via interference with signal transduction pathways may
reduce invasive properties and improve survival. Recently, we have
shown that a specific ERK-pathway inhibitor ( PD 098059 ) arrests
invasion of UM-SCC1 cells in-vitro. We therefore investigated the
effect of PD 098059 on this cell line in-vivo. Using a quantitative
orthotopic murine model, stepwise invasion of the floor-of-mouth
and tongue were evaluated after subcutaneous tumour cell
injection. Intralesional administration of PD 098059 using
liposomes as a carrier was performed over a 25 day period (every
5 days with 15mM final concentration). Tumor growth arrest and
attenuation of tumor invasion occurred in 3 of 4 treated mice;
while tumor advanced into the genioglossus muscle in 4 of 5
control mice.
Therefore the inhibition of the ERK-signal transduction pathway
may become a powerful therapeutic adjuvant in combating invasion
ofHNSCC.
Web of science
Création de la notice
22/01/2013 11:55
Dernière modification de la notice
20/08/2019 14:58
Données d'usage
